|
Dear Kahlert,
The University of Maryland School of Medicine will receive $29 million from NIH to research infectious diseases affecting people who use injectable drugs. The four-year, multicenter trial will be led by Institute for Human Virology Investigators including Kahlert Institute for Addiction Medicine's Associate Director, Sarah Kattakuzhy, MD, MPH, co-Principal Investigator Elena Rosenthal, MD, and co-Investigator Ed Traver, MD.
The Maryland Department of Health designated the Kahlert Institute for Addiction Medicine as an Overdose Response Program. To improve overdose recognition and naloxone use at UMB, Marian Cloeren, MD, MPH and Dave Barresi are leading naloxone trainings across campus and the state.
This February, the Kahlert Institute for Addiction Medicine will launch its seminar series. The series will commence with a presentation by Lorenzo Leggio, MD, PhD, Senior Investigator and Clinical Director at NIDA, on the development of innovative pharmacotherapies for addiction. Attendees will gain insights into the clinical, social, and public health consequences of alcohol and substance use disorders, and learn about key advancements in basic, translational, and clinical research with potential implications for these disorders and addictive behaviors.
Save the date for the Inaugural Research Symposium on May 6, featuring keynote speaker, Margaret Haney, PhD, Professor of Neurobiology (in Psychiatry) at Columbia University Medical Center. Additionally, the symposium will offer the latest and greatest in therapeutic approaches to addiction. Attendees will enjoy networking opportunities, a poster session, exemplary speakers, and focused sessions to foster engagement and knowledge exchange in the realm of addiction research.
The Kahlert Team
| 
